Summary:
A multi-center, randomized, double blind, placebo controlled, parallel group, phase 3 trial to evaluate the safety and efficacy of triple therapy with saxagliptin added to dapagliflozin in combination with metformin compared to therapy with placebo added to dapagliflozin in combination with metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin and dapagliflozin.
Qualified Participants Must:
• Have type 2 Diabetes treated with metformin only
•
Be at least 18 years of age
Qualified Participants May Receive:
$50.00 for completed visit for up to 13 visits, study medication, blood test, glucose testing machine, test strips and clinic visits at no charge.